UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2013-10, Vol.24 Suppl 6, p.vi160-vi170

2013

Volltextzugriff (PDF)

Long-term toxic effects of adjuvant chemotherapy in breast cancer

Annals of oncology, 2011-09, Vol.22 (9), p.1939-1947

2011

Volltextzugriff (PDF)

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies

Annals of oncology, 2015-12, Vol.26 (12), p.2408-2419

2015

Volltextzugriff (PDF)

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement

Annals of oncology, 2013-03, Vol.24 (3), p.647-654

2013

Volltextzugriff (PDF)

Understanding the biology of triple-negative breast cancer

Annals of oncology, 2012-08, Vol.23, p.vi13-vi18

2012

Volltextzugriff (PDF)

SP-0181 BREAST CANCER IN YOUNG WOMEN: ADJUVANT THERAPY AND FERTILITY CONSIDERATIONS

Radiotherapy and oncology, 2012-05, Vol.103, p.S70-S70

Azim, H.A

2012

Volltextzugriff (PDF)

IN24 Pregnancy after breast cancer

Breast (Edinburgh), 2012-11, Vol.21, p.S9-S9

Azim, H.A

2012

Volltextzugriff (PDF)

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial

Breast (Edinburgh), 2012-02, Vol.21 (1), p.27-33

2012

Volltextzugriff (PDF)

Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal

Breast (Edinburgh), 2015-08, Vol.24 (4), p.513-523

2015

Volltextzugriff (PDF)

Treatment of breast cancer during pregnancy: Regimen selection, pregnancy monitoring and more

Breast (Edinburgh), 2011-02, Vol.20 (1), p.1-6

2011

Volltextzugriff (PDF)

5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

Breast (Edinburgh), 2021-04, Vol.56, p.S21-S22

2021

Volltextzugriff (PDF)

Clinical utility of genomic tests in young women with breast cancer

Breast (Edinburgh), 2018-10, Vol.41, p.S1-S1

Azim, H.A.

2018

Volltextzugriff (PDF)

1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses

European journal of cancer (1990), 2015-09, Vol.51, p.S318-S318

2015

Volltextzugriff (PDF)

1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies

European journal of cancer (1990), 2015-09, Vol.51, p.S318-S319

2015

Volltextzugriff (PDF)

13P NON SQUAMOUS NSCLC IS MORE PLATINUM SENSITITVE THAN SQUAMOUS NSCLC

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80, p.S5-S5

2013

Volltextzugriff (PDF)

21P CLINICOPATHOLOGICAL FEATURES OF ELDERLY PATIENTS WITH NSCLC; SINGLE INSTITUTIONAL EXPERIENCE FROM EGYPT

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80, p.S9-S9

2013

Volltextzugriff (PDF)

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

Annals of oncology, 2020-06, Vol.31 (6), p.674-696

2020

Volltextzugriff (PDF)

144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy

ESMO open, 2023-05, Vol.8 (1), p.101483, Article 101483

2023

Volltextzugriff (PDF)

LBA64 Outcomes of BRCA and in-house homologous recombination deficiency (HRD) testing in women with ovarian and breast cancer: A multicentre registry study

Annals of oncology, 2024-09, Vol.35, p.S1253-S1253

2024

Volltextzugriff (PDF)

ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

Annals of oncology, 2022-11, Vol.33 (11), p.1097-1118

2022

Volltextzugriff (PDF)

P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer

Breast (Edinburgh), 2015-03, Vol.24, p.S60-S61

2015

Volltextzugriff (PDF)

62P Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial

Annals of oncology, 2023-11, Vol.34, p.S1490

2023

Volltextzugriff (PDF)

ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

Annals of oncology, 2023-10, Vol.34 (10), p.849-866

2023

Volltextzugriff (PDF)

34P Quadruple-negative breast cancer (PD-L1-negative triple-negative breast cancer, TNBC): Poorer response to chemotherapy and poorer survival compared to other TNBCs: A systematic review and meta-analysis

Annals of oncology, 2022-05, Vol.33, p.S138-S138

2022

Volltextzugriff (PDF)

103IN - Is the Neoadjuvant Model an Accelerated Path Towards Breast Cancer Treatment Tailoring? Experience of the Neoaltto Trial

Annals of oncology, 2012-09, Vol.23, p.ix58-ix58

2012

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(87)
Tagungsberichte
(1)

Sprache

Englisch
(88)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Long-term toxic effects of adjuvant chemotherapy in breast cancer

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement

Understanding the biology of triple-negative breast cancer

SP-0181 BREAST CANCER IN YOUNG WOMEN: ADJUVANT THERAPY AND FERTILITY CONSIDERATIONS

IN24 Pregnancy after breast cancer

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial

Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal

Treatment of breast cancer during pregnancy: Regimen selection, pregnancy monitoring and more

5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

Clinical utility of genomic tests in young women with breast cancer

1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses

1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies

13P NON SQUAMOUS NSCLC IS MORE PLATINUM SENSITITVE THAN SQUAMOUS NSCLC

21P CLINICOPATHOLOGICAL FEATURES OF ELDERLY PATIENTS WITH NSCLC; SINGLE INSTITUTIONAL EXPERIENCE FROM EGYPT

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy

LBA64 Outcomes of BRCA and in-house homologous recombination deficiency (HRD) testing in women with ovarian and breast cancer: A multicentre registry study

ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer

62P Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial

ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

34P Quadruple-negative breast cancer (PD-L1-negative triple-negative breast cancer, TNBC): Poorer response to chemotherapy and poorer survival compared to other TNBCs: A systematic review and meta-analysis

103IN - Is the Neoadjuvant Model an Accelerated Path Towards Breast Cancer Treatment Tailoring? Experience of the Neoaltto Trial

Suchergebnisse filtern